News >

Atezolizumab Plus Chemo Improves PFS in Frontline Squamous NSCLC

Jason M. Broderick @jasoncology
Published: Tuesday, Mar 20, 2018

Dr. Sandra Horning
Sandra Horning, MD
The addition of atezolizumab (Tecentriq) to frontline carboplatin and nab-paclitaxel (Abraxane) delayed progression or death compared with chemotherapy alone for patients with advanced squamous non–small cell lung cancer (NSCLC), according to topline findings from the phase III IMpower131 trial released by Genentech (Roche), the manufacturer of the anti–PD-L1 agent.

Previously reported results from a phase Ib trial presented at the 2015 World Conference on Lung Cancer demonstrated the promise of combining frontline atezolizumab with chemotherapy in patients with metastatic NSCLC.1 Patients received atezolizumab at a dose of 15 mg/kg IV every 3 weeks in addition to 1 of 3 chemotherapy doublets: carboplatin paired with paclitaxel, pemetrexed (nonsquamous histology only), or nab-paclitaxel. Treatment continued for 4 to 6 cycles, followed by atezolizumab maintenance therapy until disease progression (and optionally, pemetrexed maintenance in that arm of the trial).

The primary outcome was overall response rate, as determined by RECIST criteria. Data were reported for 58 patients, 41 of whom were evaluable for response. The patients had a median age of 65, and 79% of the cohort had nonsquamous histology. 

Overall, 26 (63.4%) of the 41 evaluable patients met the criteria for objective response. Four of 8 (50%) patients in the atezolizumab plus carboplatin/paclitaxel cohort achieved objective responses (all partial responses). The combination of atezolizumab, carboplatin, and pemetrexed induced a response in 13 (76.5%) of 17 patients (all partial responses). Responses also occurred in 9 (56%) of 16 patients who received carboplatin and nab-paclitaxel in addition to atezolizumab. 

Data from the phase III IMpower150 trial reported in December at the ESMO Immuno Oncology Congress showed that the frontline combination of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel delayed progression or death by 38% compared with bevacizumab and chemotherapy alone for patients with advanced nonsquamous NSCLC.2

The atezolizumab regimen demonstrated a median PFS of 8.3 months compared with 6.8 months with bevacizumab and chemotherapy alone (HR, 0.62; 95% CI, 0.52-0.74; P <.0001). The 12-month PFS rate was 37% with the atezolizumab-containing regimen and 18% with the bevacizumab/chemotherapy regimen.

In a preliminary examination of OS, there was a 22.5% reduction in the risk of death with the atezolizumab combination compared with bevacizumab and chemotherapy alone. After a minimum follow-up of 9.5 months, the median OS was 14.4 (95% CI, 12.8-17.1) versus 19.2 months (95% CI, 16.8-26.1), in favor of the atezolizumab group (HR, 0.775; 95% CI, 0.619-0.970; P = .0262). The next OS analysis will take place in the first half of 2018.


  1. Camidge R, Liu SV, Powderly J, et al. Atezolizumab (MPDL3280A) combined with platinum-based chemotherapy in non–small cell lung cancer (NSCLC): a phase Ib safety and efficacy update. Presented at: 16th World Conference on Lung Cancer; September 6-9; Denver, CO. Abstract 02.07.
  2. Reck M. Primary PFS and safety analyses of a randomized Phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMpower150). Annals of Oncology, 2017;28(11). Abstract LBA1_PR.


... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Oncology Nursing News
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
OncLive Resources

Conference Coverage
OncLive TV
Peer Exchange
Web Exclusives

About Us
Advisory Board
Contact Us
Forgot Password
Press Releases
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-939-0221

Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.